The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.

Combatting Future Viral Threats with Vaccine Advances

More technologies and treatments are emerging for COVID-19—along with new variants.

What’s Next for COVID-19 Vaccines and Variants?

Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.

Key Elements for Assay Transfer Success

Topic

Articles

Moderna’s mRNA-1273.214 booster candidate exhibited an eight-fold boost in neutralizing geometric mean titers against Omicron.

Moderna Bivalent Booster Candidate Demonstrates Superior Antibody Response Against Omicron

The agency’s Medicines Shortages Steering Group has adopted a list of critical COVID-19 vaccines and treatments so they may be monitored for potential shortages.

EMA Adopts List of Critical COVID-19 Medicines

Pfizer will invest $120 million to produce COVID-19 oral treatment in the US. 

Pfizer to Invest $120 Million in COVID-19 Oral Treatment Production

Bianca Piachaud-Moustakis is lead writer at Pharmavision, Pharmavision.co.uk.

EMA has been assigned a formal role in preparing for and managing future public health crises within the EU through the formalization of ad-hoc structures and processes that were employed during the COVID-19 pandemic.

Enhanced Role of EMA in EU Crisis Response

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

The Next Pandemic

AstraZeneca's recombinant COVID-19 vaccine, originally invented by the University of Oxford, has been approved as a third dose booster vaccine in the EU.

Vaxzevria Gains Approval in EU as a Third Dose COVID-19 Booster in Adults

Investment has been made into a new science hub at the University of Edinburgh for the development of treatments for lung infections and future pandemics.

Pandemic Science Hub Launches at University of Edinburgh

AstraZeneca has signed a license agreement with RQ Biotechnology for monoclonal antibodies to treat COVID-19.

AstraZeneca and RQ Biotechnology Sign License Agreement for Monoclonal Antibodies

Pfizer and BioNTech’s COVID-19 vaccine has been granted EUA for booster doses in children five through 11 years of age.

Pfizer and BioNTech Granted EUA for Booster Dose of COVID-19 Vaccine in Young Children

The companies have reached an agreement with the European Commission to update their COVID-19 vaccine supply agreement.

COVID-19 Update

Combatting Future Viral Threats with Vaccine Advances

What’s Next for COVID-19 Vaccines and Variants?

Key Elements for Assay Transfer Success